Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 265 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glomerulonephritis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Nephrotic Syndrome, Membranous Nephropathy
Interventions
Apixaban 5 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 79 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced May 21, 2026, 10:11 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
PS-002
Genetic
Lead sponsor
Purespring Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 21, 2026, 10:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Focal Glomerulosclerosis
Interventions
Rosiglitazone (Avandia), Adalimumab (Humira)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2007 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Lupus Nephritis
Interventions
CNTO 136, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions
Pirfenidone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced May 21, 2026, 10:11 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
Interventions
zigakibart
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Denver, Colorado • Orlando, Florida • Clifton Park, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 10:11 PM EDT
Not listed Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Interventions
ACTHAR Gel (adrenocorticotropic hormone)
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced May 21, 2026, 10:11 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
TRU-015
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced May 21, 2026, 10:11 PM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • New York, New York • Morrisville, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 10:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis
Interventions
Rituximab Infusion, Oral Cyclosporine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
Interventions
Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 10:11 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Rituximab, Plasmapheresis
Drug · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
1 Year to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Tuscaloosa, Alabama • Davis, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Hepatitis B, Chronic Hepatitis D, Glomerulonephritis, Polyarteritis Nodosa
Interventions
Lamivudine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 10:11 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Placebo, Atacicept 25 mg, Atacicept 75 mg
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Glendale, Arizona • Chula Vista, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BI 655064, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Plantation, Florida • Great Neck, New York • Manhasset, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Kidney Disease, Glomerulonephritis
Interventions
Mezagitamab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Northridge, California • Nampa, Idaho • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced May 21, 2026, 10:11 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Galactose
Drug
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced May 21, 2026, 10:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Immunoglobulin A Nephropathy (IgAN)
Interventions
zigakibart
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Denver, Colorado • Acworth, Georgia • Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Doral, Florida • Kissimmee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced May 21, 2026, 10:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced May 21, 2026, 10:11 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Lupus Erythematosus, Lupus Nephritis
Interventions
Itolizumab [Bmab 600]
Drug
Lead sponsor
Equillium
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
19
States / cities
Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced May 21, 2026, 10:11 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Interventions
Iptacopan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 10:11 PM EDT